SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — May 29, 2018
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: May 29, 2018 · CIK: 0001368514 · Accession: 0001193805-18-000766
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225048
Letter
Via EDGAR Securities and Exchange Commission Division of Corporation Finance Attn: Mary Beth Breslin Re: ADMA Biologics, Inc. (the “Company”)Registration Statement on Form S-3 Filed May 18, 2018, as amended File No. 333-225048
Dear Ms. Breslin:
The Company hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. (EST) on May 31, 2018, or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as amended.
The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact David C. Schwartz, Esq. of DLA Piper LLP (US) with any questions or comments at (973) 520-2555. Thank you for your assistance with this filing.
ADMA BIOLOGICS, INC.
By: /s/ Adam S. Grossman
Name: Adam S. Grossman
Title: President and Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
ADMA Biologics, Inc.
465 State Route 17
Ramsey, New Jersey 07446
May 29, 2018
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-4561
Attn: Mary Beth Breslin
Re: ADMA Biologics, Inc. (the “Company”)Registration
Statement on Form S-3
Filed May 18,
2018, as amended
File No. 333-225048
Dear Ms. Breslin:
The Company hereby
requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective
at 4:00 p.m. (EST) on May 31, 2018, or as soon as practicable thereafter, pursuant to Rule 461 of the Securities Act of 1933, as
amended.
The Company acknowledges
that (i) should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission, acting pursuant
to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action
with respect to the filing; (ii) the action of the Commission or the staff of the Commission, acting pursuant to delegated authority,
in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense
in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact David
C. Schwartz, Esq. of DLA Piper LLP (US) with any questions or comments at (973) 520-2555. Thank you for your assistance with this
filing.
ADMA BIOLOGICS, INC.
By:
/s/ Adam S. Grossman
Name:
Adam S. Grossman
Title:
President and Chief Executive Officer